AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29145873 — intervention group
Group type: COMPARATOR
Intervention: Individual pelvic floor muscle training (PFMT)
Number of subjects: 364
Study 29145873 — intervention group
Group type: EXPERIMENTAL
Intervention: Group pelvic floor muscle training (PFMT)
Number of subjects: 364
Study 25657053 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Self-Management Intervention (PASM), n = 149
Number of subjects: 325
Study 25657053 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC), n = 156
Number of subjects: 325
Study 24704942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and endobronchial photodynamic therapy (PDT) with photosensitizer agent chlorine E6 and 662nm laser light before each of the three courses of chemotherapy.
Number of subjects: 42
Study 24704942 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (No-PDT arm).
Number of subjects: 42
Study 24704942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and endobronchial PDT (PDT arm).
Number of subjects: 42
Study 22791944 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural combined general anesthesia (G + E)
Number of subjects: 61
Study 22791944 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (G)
Number of subjects: 61
Study 18955144 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 18955144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17214829 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 24
Study 17214829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15385354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the first tactile TOF response (Group I)
Number of subjects: 160
Study 15385354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the second tactile TOF response (Group II)
Number of subjects: 160
Study 15385354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the third tactile TOF response (Group III)
Number of subjects: 160
Study 15385354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the fourth tactile TOF response (Group IV)
Number of subjects: 160
Study 15385354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the first tactile TOF response (Group I) during sevoflurane anesthesia
Number of subjects: 160
Study 15385354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the second tactile TOF response (Group II) during sevoflurane anesthesia
Number of subjects: 160
Study 15385354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the third tactile TOF response (Group III) during sevoflurane anesthesia
Number of subjects: 160
Study 15385354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the fourth tactile TOF response (Group IV) during sevoflurane anesthesia
Number of subjects: 160
Study 11477585 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using meta-tetra(hydroxyphenyl)chlorin (m-THPC) at a dose of 0.10 mg/kg bodyweight, irradiated 48 hours after drug application at a light dose of 5 J/cm².
Number of subjects: 7
Study 11477585 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using meta-tetra(hydroxyphenyl)chlorin (m-THPC) at a dose of 0.15 mg/kg bodyweight, illuminated 96 hours after photosensitization at a light dose of 10 J/cm².
Number of subjects: 7
Study 11477585 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using m-THPC.
Number of subjects: 7
Study 9748876 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b
Number of subjects: 55
Study 9748876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential maintenance therapy (interferon alpha-2b for 3 months followed by dexamethasone)
Number of subjects: 55
Study 9748876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with melphalan (200 mg/m2)
Number of subjects: 55
Study 7923515 — intervention group
Group type: EXPERIMENTAL
Intervention: High epidural anaesthesia
Number of subjects: 20
Study 7923515 — intervention group
Group type: EXPERIMENTAL
Intervention: Low epidural anaesthesia
Number of subjects: 20
Study 7923515 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study 2902792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 54
Study 2902792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg
Number of subjects: 54
Study 2902792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 90 mg
Number of subjects: 54
Study 2902792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31119583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (10 g kg−1 CDXOS)
Number of subjects: 80
Study 31119583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 3 (108 CFU g−1 L. plantarum CR1T5)
Number of subjects: 80
Study 31119583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 4 (10 g kg−1 CDXOS + 108 CFU g−1 L. plantarum CR1T5)
Number of subjects: 80
Study 31119583 — intervention group
Group type: COMPARATOR
Intervention: Control (diet 1)
Number of subjects: 80
Study 29893446 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 942
Study 29893446 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretic
Number of subjects: 942
Study 29893446 — intervention group
Group type: COMPARATOR
Intervention: Serum chloride levels
Number of subjects: 942
Study 28277290 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid with patient narratives (Group 1)
Number of subjects: 210
Study 28277290 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid without patient narratives (Group 2)
Number of subjects: 210
Study 28277290 — intervention group
Group type: COMPARATOR
Intervention: Standard information (Control Group 3)
Number of subjects: 210
Study 26712393 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation group (n = 47)
Number of subjects: 188
Study 26712393 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 141)
Number of subjects: 188
Study 22532169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective handwriting assessment (micrographia, normal, macrographia)
Number of subjects: 66
Study 22532169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective handwriting assessment (macrographia)
Number of subjects: 66
Study 22532169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective handwriting assessment (micrographia)
Number of subjects: 66
Study 22532169 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective handwriting metrics
Number of subjects: 66
Study 20151804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD; 20 mg two times a day)
Number of subjects: 128
Study 20151804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 17531899 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of gestational diabetes mellitus (GDM)
Number of subjects: 0
Study 17531899 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for postpartum glucose intolerance
Number of subjects: 0
Study 17531899 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to risk factors and plasma glucose status
Number of subjects: 0
Study 16109560 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-CH (10 mg Epi-CH injected around the primary tumor or biopsy excision 72 h before operation)
Number of subjects: 60
Study 16109560 — intervention group
Group type: COMPARATOR
Intervention: Control (10 mg epirubicin solution injected in the same region)
Number of subjects: 60
Study 16109560 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-CH
Number of subjects: 60
Study 12049562 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-mediated ablation (PMA)
Number of subjects: 34
Study 12049562 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrosurgery (MES)
Number of subjects: 34
Study 9527292 — intervention group
Group type: EXPERIMENTAL
Intervention: Back class teaching extension exercises
Number of subjects: 75
Study 9527292 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (Control)
Number of subjects: 75
Study 7630622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine factor VIII derivative (vascular factor, VF)
Number of subjects: 19
Study 7630622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms by metered dose inhaler)
Number of subjects: 0
Study 2572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (0.5 mg by oral route)
Number of subjects: 0
Study 2572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (0.25 mg as nebulizer solution)
Number of subjects: 0
Study 2572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (oral and aerosol administration)
Number of subjects: 0
Study 2572037 — intervention group
Group type: COMPARATOR
Intervention: Broxaterol (400 micrograms by aerosol)
Number of subjects: 0
Study 2572037 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (500 micrograms)
Number of subjects: 0
Study 2572037 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (400 micrograms)
Number of subjects: 0
Study 2572037 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (aerosol)
Number of subjects: 0
Study 835376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound method for determining effective orifice area
Number of subjects: 10
Study 835376 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheterization methods
Number of subjects: 10
Study 31302586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-NAT TILs
Number of subjects: 209
Study 31302586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-NAT TILs in TNBC with RD
Number of subjects: 209
Study 31302586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low post-NAT TILs in TNBC with RD
Number of subjects: 209
Study 31302586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-NAT TILs in HER2+ BC
Number of subjects: 209
Study 29364767 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus standard medical therapy
Number of subjects: 182
Study 29364767 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 182
Study 27595680 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg BID, with a possible reduction to 2.5 mg BID based on certain criteria; single starting dose of 10 mg or 5 mg if down-titrated)
Number of subjects: 1500
Study 27595680 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus warfarin
Number of subjects: 1500
Study 24958908 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir-based ART
Number of subjects: 389
Study 24958908 — intervention group
Group type: COMPARATOR
Intervention: efavirenz-based ART
Number of subjects: 389
Study 21884019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates training for 16 weeks, 30 min of aerobic exercise followed by 20 min of Pilates.
Number of subjects: 16
Study 21884019 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation program for 16 weeks, 30 min of aerobic exercise followed by 15 min calisthenics exercise.
Number of subjects: 16
Study 20043705 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone peer support (intervention group, n = 38)
Number of subjects: 78
Study 20043705 — intervention group
Group type: COMPARATOR
Intervention: No telephone peer support (control group, n = 40)
Number of subjects: 78
Study 20043705 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone peer support (intervention group, n = 13 exclusively breastfeeding at discharge)
Number of subjects: 78
Study 20043705 — intervention group
Group type: COMPARATOR
Intervention: No telephone peer support (control group, n = 11 exclusively breastfeeding at discharge)
Number of subjects: 78
Study 18608712 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (Iso) therapy for cystic acne for 45 days
Number of subjects: 74
Study 18608712 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 74
Study 18608712 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (Iso) therapy for cystic acne
Number of subjects: 74
Study 16182139 — intervention group
Group type: EXPERIMENTAL
Intervention: web SAQ
Number of subjects: 1918
Study 16182139 — intervention group
Group type: COMPARATOR
Intervention: paper SAQ
Number of subjects: 1918
Study 12381942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calcium acetate (1,521 mg calcium/day)
Number of subjects: 0
Study 12381942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose calcium acetate (507 mg calcium/day)
Number of subjects: 0
Study 10195547 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Laryngeal Mask Airway (FLMA)
Number of subjects: 20
Study 10195547 — intervention group
Group type: COMPARATOR
Intervention: Standard Laryngeal Mask Airway (LMA)
Number of subjects: 20
Study 10195547 — intervention group
Group type: COMPARATOR
Intervention: LMA
Number of subjects: 20
Study 10195547 — intervention group
Group type: EXPERIMENTAL
Intervention: FLMA
Number of subjects: 20
Study 10195547 — intervention group
Group type: EXPERIMENTAL
Intervention: FLMA and LMA
Number of subjects: 20
Study 7781936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group (500 mg amoxicillin q.i.d. and 500 mg tinidazole t.i.d. for 1 week)
Number of subjects: 119
Study 7781936 — intervention group
Group type: COMPARATOR
Intervention: Maintenance group (40 mg famotidine for 6 weeks followed by 20 mg famotidine at bedtime for 6 months)
Number of subjects: 119
Study 7781936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group
Number of subjects: 119
Study 7781936 — intervention group
Group type: COMPARATOR
Intervention: Maintenance group
Number of subjects: 119
Study 7781936 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group (H. pylori negative)
Number of subjects: 119
Study 2195108 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 3 U/h and glucagon 200 micrograms/h in 5% dextrose with 1% human albumin solution (HAS)
Number of subjects: 18
Study 2195108 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose and HAS alone (Control)
Number of subjects: 18
Study 2195108 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glucagon therapy
Number of subjects: 18
Study 44117 — intervention group
Group type: EXPERIMENTAL
Intervention: tween‐ether‐split‐vaccine
Number of subjects: 207
Study 44117 — intervention group
Group type: COMPARATOR
Intervention: subunit‐vaccine
Number of subjects: 207
Study 31650685 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Bite Group (OBG)
Number of subjects: 90
Study 31650685 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Bite Group (NBG)
Number of subjects: 90
Study 31650685 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Bite Group (DBG)
Number of subjects: 90
Study 31063671 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 80
Study 31063671 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 80
Study 29100778 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with tuberculosis regimen
Number of subjects: 319
Study 29100778 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 319
Study 25892434 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (4-6 months)
Number of subjects: 64
Study 25892434 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment with loperamide and stool-bulking agents (2 months)
Number of subjects: 64
Study 25892434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (biofeedback + medical treatment)
Number of subjects: 64
Study 23928167 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based adherence support intervention
Number of subjects: 250
Study 23928167 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 250
Study 23928167 — intervention group
Group type: COMPARATOR
Intervention: Other clinic patients (not part of the intervention or control)
Number of subjects: 250
Study 21362275 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 28
Study 21362275 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 28
Study 19920269 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (bimonthly tailored, nurse-administered telephone intervention targeting hypertension-related behaviors)
Number of subjects: 636
Study 19920269 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP monitoring (3 times weekly)
Number of subjects: 636
Study 19920269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (behavioral intervention plus home BP monitoring)
Number of subjects: 636
Study 19920269 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 636
Study 17920887 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis (TMK)
Number of subjects: 40
Study 17920887 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing device (AGC)
Number of subjects: 40
Study 17920887 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral arthroplasty with TMK
Number of subjects: 40
Study 15657164 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Number of subjects: 0
Study 15657164 — intervention group
Group type: COMPARATOR
Intervention: Contemporary medical practice
Number of subjects: 0
Study 11923755 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection therapy with epinephrine‐polidocanol (1%)
Number of subjects: 101
Study 11923755 — intervention group
Group type: COMPARATOR
Intervention: Hemoclip application
Number of subjects: 101
Study 11923755 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection combined with hemoclip
Number of subjects: 101
Study 9874432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (3 x 50 mg intravenously)
Number of subjects: 158
Study 9874432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (3 x 10 mg intravenously)
Number of subjects: 158
Study 9874432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 7711365 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for chronic low-back pain
Number of subjects: 456
Study 7711365 — intervention group
Group type: COMPARATOR
Intervention: Spinal rotation measurements
Number of subjects: 456
Study 2560684 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg s.c.)
Number of subjects: 6
Study 2560684 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg i.v., ITT)
Number of subjects: 6
Study 2560684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1000228 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant heater group
Number of subjects: 56
Study 1000228 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant heater group (babies < 1500 g)
Number of subjects: 56
Study 1000228 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant heater group (babies < 1000 g)
Number of subjects: 56
Study 1000228 — intervention group
Group type: COMPARATOR
Intervention: Incubator group (babies < 1000 g)
Number of subjects: 56
Study 31511286 — intervention group
Group type: COMPARATOR
Intervention: Short interval (<3 years) between menarche and first sexual intercourse (FSI) or start of oral contraceptive (OC) use
Number of subjects: 913
Study 31511286 — intervention group
Group type: COMPARATOR
Intervention: Long interval (≥3 years) between menarche and FSI or start of OC use
Number of subjects: 913
Study 31511286 — intervention group
Group type: COMPARATOR
Intervention: Early age at start of OC use in women with a short interval between menarche and FSI
Number of subjects: 913
Study 28608926 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg plus ethanol 0.4 g/kg
Number of subjects: 1543
Study 28608926 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg plus ethanol 0.8 g/kg
Number of subjects: 1543
Study 28608926 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg
Number of subjects: 1543
Study 28608926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1543
Study 28608926 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg plus ethanol
Number of subjects: 1543
Study 26392753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (daily 12.55 mg)
Number of subjects: 120
Study 26392753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24313577 — intervention group
Group type: EXPERIMENTAL
Intervention: Camouflage Syringe
Number of subjects: 0
Study 21649532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product containing Ile-Pro-Pro and Val-Pro-Pro (25 mg peptides and 2 g plant sterols)
Number of subjects: 25
Study 21649532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19293009 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol peels
Number of subjects: 46
Study 17129925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (stress inoculation training)
Number of subjects: 28
Study 17129925 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment (cyclobenzaprine)
Number of subjects: 28
Study 17129925 — intervention group
Group type: COMPARATOR
Intervention: Combined pharmacological and cognitive-behavioral treatment
Number of subjects: 28
Study 17129925 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28
Study 14715848 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/d)
Number of subjects: 30
Study 14715848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (1 mg/d 17beta‐estradiol combined with norethisterone acetate)
Number of subjects: 30
Study 14715848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30